Gilead, Kite pen natural killer pact with little-known Australian cell therapy player

All the attention is currently laser-focused on Gilead Sciences' COVID-19 hopeful remdesivir, but the company itself is still penning deals outside of infectious disease.

Through its $12.9 billion biotech buy Kite Pharma, the Californian company has inked a new deal with an almost unknown Australian biotech: oNKo-innate.

The purpose of the deal is for Gilead and Kite to tap into the biotech’s natural killer (NK) work in order to seek out new cell therapies and build on its CAR-T research.